Negotiating NASH

Why NEA thinks Metacrine’s FXR agonist could be best in class for NASH

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis.

Metacrine closed an untranched $22 million series B round led by new investor NEA on Dec.

Read the full 411 word article

User Sign In